You are here: Home » International » News » Others
Business Standard

Covid-19 crisis: Oxford scientists expect vaccine data by Christmas

Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal

Topics
Coronavirus | Oxford University | Christmas

AP  |  London 

oxford, vaccine trials, coronavirus, covid-19

University of Oxford scientists expect to report results from the late-stage trials of their COVID-19 vaccine by Christmas, a key researcher said on Thursday as he discussed the team's latest findings.

Dr Andrew Pollard, an expert in pediatric infection and immunity at Oxford, said research was slowed by low infection rates over the summer, but the Phase III trials are now accumulating the data needed to report results as a renewed surge of the pandemic hits countries around the world. Oxford is developing its vaccine in conjunction with the drugmaker AstraZeneca.

I think we're getting close, and it's definitely going to be before based on the progress, Pollard said in an interview with the BBC.

Two other drugmakers, Pfizer and Moderna, this week reported preliminary results from late-stage trials showing that their COVID-19 vaccines were almost 95% effective.

Pollard said there is no competition between the various research teams, because several vaccines will be needed to bring the global pandemic under control and allow life to return to normal.

Despite recent progress, Pollard said the world is still in the early stages of the effort to protect people against COVID-19. Even after vaccines are approved by regulators, drugmakers and public health officials still face the task of producing billions of doses and administering them to people around the world, he said.

Pollard, an amateur mountaineer, compared the task to the work involved in climbing a mountain.

I think we're still at the bottom of that mountain in some ways, he said.

We've done the route into the bottom of the mountain, the long trek to get to the start. Now we've got to get the data about the vaccines in front of regulators for them to scrutinise it and approve the first vaccines. And then we've got that huge effort to climb up to the top where we've got a vast majority of those who are at risk vaccinated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 20 2020. 00:51 IST
RECOMMENDED FOR YOU
.